active not recruiting
Phase I
Oncology
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
First-in-human trial testing safety, tolerability, and cancer-fighting activity of a new radioactive targeted treatment for advanced prostate cancer.
15 Jun 2026
NCT06052306